{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:02:38Z","timestamp":1778371358973,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40520-018-0956-3","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T04:21:21Z","timestamp":1525234881000},"page":"693-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies"],"prefix":"10.1007","volume":"30","author":[{"given":"Ermanno","family":"Zorzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gabutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"956_CR1","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division (2017) World population prospects: The 2017 revision, key findings and advance tables. Working paper no. ESA\/P\/WP\/248. https:\/\/esa.un.org\/unpd\/wpp\/Publications\/Files\/WPP2017_KeyFindings.pdf. Accessed 10 July 2017"},{"key":"956_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/gerona\/59.3.M255","volume":"59","author":"LP Fried","year":"2004","unstructured":"Fried LP, Ferrucci L, Darer J et al. (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59:255\u2013263","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"956_CR3","doi-asserted-by":"publisher","first-page":"M146-56","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J et al (2001) Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-56","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"956_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C et al (2005) A global clinical measure of fitness and frailty in elderly people. CMAJ 173:489\u2013495","journal-title":"CMAJ"},{"key":"956_CR5","unstructured":"British Geriatrics Society (2014) Fit for Frailty\u2014consensus best practice guidance for the care of older people living in community and outpatient settings\u2014a report from the British Geriatrics Society"},{"key":"956_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1017\/S0959259802012236","volume":"12","author":"K Rockwood","year":"2002","unstructured":"Rockwood K, Mitnitski A, MacKnight C (2002) Some mathematical models of frailty and their clinical implications. Rev Clin Gerontol 12:109\u2013117","journal-title":"Rev Clin Gerontol"},{"key":"956_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jamda.2009.09.015","volume":"11","author":"RJ Gobbens","year":"2010","unstructured":"Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT et al. (2010) In search of an integral conceptual definition of frailty: opinions of experts. J Am Med Dir Assoc 11:338\u2013343","journal-title":"J Am Med Dir Assoc"},{"key":"956_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381 868","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S et al. (2013) Frailty in elderly people. Lancet 381 868:752\u2013762","journal-title":"Lancet"},{"key":"956_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2017.01.006","volume":"36","author":"D Wilson","year":"2017","unstructured":"Wilson D, Jackson T, Sapey E et al. (2017) Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev 36:1\u201310","journal-title":"Ageing Res Rev"},{"key":"956_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s11357-012-9396-8","volume":"35","author":"D Baylis","year":"2013","unstructured":"Baylis D, Bartlett DB, Syddall HE et al (2013) Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age (Dordr) 35:963\u2013971","journal-title":"Age (Dordr)"},{"key":"956_CR11","first-page":"1","volume":"24","author":"GC Wang","year":"2014","unstructured":"Wang GC, Casolaro V (2014) Immunologic changes in frail older adults. Transl Med UniSa 24:1\u20136","journal-title":"Transl Med UniSa"},{"key":"956_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1742-4933-6-10","volume":"6","author":"C Caruso","year":"2009","unstructured":"Caruso C, Buffa S, Candore G et al (2009) Mechanisms of immunosenescence. Immun Ageing 6:10","journal-title":"Immun Ageing"},{"key":"956_CR13","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"JI Cohen","year":"2014","unstructured":"Cohen JI (2014) Introduction to Herpesviridae. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases, 8th\u00a0edn. Elsevier, Philadelphia","edition":"8"},{"key":"956_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/jgs.14090","volume":"64","author":"GC Wang","year":"2016","unstructured":"Wang GC, Han C, Detrick B et al (2016) Herpesvirus infections and risk of frailty and mortality in older women: Women\u2019s Health and Aging Studies. J Am Geriatr Soc 64:998\u20131005","journal-title":"J Am Geriatr Soc"},{"key":"956_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1742-4933-10-30","volume":"10","author":"MB Haeseker","year":"2013","unstructured":"Haeseker MB, Pijpers E, Dukers-Muijrers NH et al (2013) Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study. Immun Ageing 10:30","journal-title":"Immun Ageing"},{"key":"956_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10522-015-9577-9","volume":"17","author":"D Goldeck","year":"2016","unstructured":"Goldeck D, Pawelec G, Norman K et al (2016) No strong correlations between serum cytokine levels, CMV serostatus and hand-grip strength in older subjects in the Berlin BASE-II cohort. Biogerontology 17:189\u2013198","journal-title":"Biogerontology"},{"key":"956_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.coi.2012.06.002","volume":"24","author":"MJ Levin","year":"2012","unstructured":"Levin MJ (2012) Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 24:494\u2013500","journal-title":"Curr Opin Immunol"},{"key":"956_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1086\/605611","volume":"200","author":"A Weinberg","year":"2009","unstructured":"Weinberg A, Zhang JH, Oxman MN et al (2009) US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200:1068\u20131077","journal-title":"J Infect Dis"},{"key":"956_CR19","unstructured":"SAGE Working Group on Varicella and Herpes Zoster Vaccines. Background paper on Herpes zoster vaccines. 2014 Mar. http:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/april\/2_Background_document_Herpes_Zoster.pdf?ua=1. Accessed 10 July 2017"},{"key":"956_CR20","first-page":"17","volume-title":"Herpes zoster e nevralgia post-erpetica","author":"E Franco","year":"2016","unstructured":"Franco E, Zorzoli E, Valente N et al. (2016) Aspetti epidemiologici dell\u2019Herpes zoster e della nevralgia post-erpetica [Epidemiological aspects of Herpes zoster and post-herpetic neuralgia]. In: Gabutti G (ed) Herpes zoster e nevralgia post-erpetica. Edizioni Minerva medica, Torino, pp\u00a017\u201326 (Italian)"},{"key":"956_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","volume":"17","author":"L Varghese","year":"2017","unstructured":"Varghese L, Standaert B, Olivieri A et al. (2017) The temporal impact of aging on the burden of herpes zoster. BMC Geriatr 17:30","journal-title":"BMC Geriatr"},{"key":"956_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40520-015-0314-7","volume":"27","author":"S Maggi","year":"2015","unstructured":"Maggi S, Gabutti G, Franco E et al (2015) Preventing and managing herpes zoster: key actions to foster healthy aging. Aging Clin Exp Res 27:5\u201311","journal-title":"Aging Clin Exp Res"},{"key":"956_CR23","unstructured":"WHO. Active ageing: a policy framework. WHO\/NMH\/NPH\/02.8. 2002. http:\/\/apps.who.int\/iris\/bitstream\/10665\/67215\/1\/WHO_NMH_NPH_02.8.pdf. Accessed 10 July 2017"},{"key":"956_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/21645515.2017.1264831","volume":"13","author":"G Gabutti","year":"2017","unstructured":"Gabutti G, Bonanni P, Conversano M et al (2017) Prevention of Herpes Zoster and its complications: from clinical evidence to real life experience. Hum Vaccin Immunother 13:391\u2013398","journal-title":"Hum Vaccin Immunother"},{"key":"956_CR25","first-page":"9","volume-title":"Herpes zoster e nevralgia post-erpetica","author":"A Stefanati","year":"2016","unstructured":"Stefanati A, Kuhdari P, Bertoni L et al. (2016) Storia naturale e risposta immunitaria nell\u2019infezione da Varicella-zoster virus: varicella ed Herpes zoster [Natural history and immune response in Varicella-zoster virus infection: varicella and herpes zoster]. In: Gabutti G (ed) Herpes zoster e nevralgia post-erpetica. Edizioni Minerva medica, Torino, pp\u00a09\u201316 Italian."},{"key":"956_CR26","first-page":"39","volume-title":"Herpes zoster and post-herpetic neuralgia","author":"RH Dworkin","year":"2001","unstructured":"Dworkin RH, Schmader KE (2001) The epidemiology and natural history of herpes zoster and post-herpetic neuralgia. In: Watson CP, Gershon AA (eds) Herpes zoster and post-herpetic neuralgia, 2nd\u00a0edn. Elsevier Press, New York, pp\u00a039\u201364","edition":"2"},{"key":"956_CR27","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","volume":"48","author":"AA Gershon","year":"2010","unstructured":"Gershon AA, Gershon MD, Breuer J et al (2010) Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 48:S2\u2013S7","journal-title":"J Clin Virol"},{"key":"956_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/fampra\/19.5.471","volume":"19","author":"W Opstelten","year":"2002","unstructured":"Opstelten W, Mauritz JW, de Wit NJ, et al (2002) Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 19:471\u2013475","journal-title":"Fam Pract"},{"key":"956_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI (2013) Clinical practice: Herpes zoster. N Engl J Med 369:255\u2013263","journal-title":"N Engl J Med"},{"key":"956_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s12879-014-0637-6","volume":"14","author":"H Bricout","year":"2014","unstructured":"Bricout H, Perinetti E, Marchettini P et al (2014) Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009\u20132010): a GP-based prospective cohort study. BMC Infect Dis 14:637","journal-title":"BMC Infect Dis"},{"key":"956_CR31","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ (2014) Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4:e004833","journal-title":"BMJ Open"},{"key":"956_CR32","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1212\/01.WNL.0000123261.00004.29","volume":"62","author":"BF Jung","year":"2004","unstructured":"Jung BF, Johnson RW, Griffin DRJ, et al (2004) Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62:1545\u20131551","journal-title":"Neurology"},{"key":"956_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcv.2007.01.010","volume":"38","author":"A Volpi","year":"2007","unstructured":"Volpi A, Gatti A, Serafini G et al (2007) Clinical and psychosocial correlates of acute pain in herpes zoster. J Clin Virol 38:275\u2013279","journal-title":"J Clin Virol"},{"key":"956_CR34","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/jmv.21254","volume":"80","author":"A Volpi","year":"2008","unstructured":"Volpi A, Gatti A, Pica F et al (2008) Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 80:1646\u20131652","journal-title":"J Med Virol"},{"key":"956_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/jmv.21748","volume":"82","author":"A Gatti","year":"2010","unstructured":"Gatti A, Pica F, Boccia MT et al (2010) No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. J Med Virol 82:1007\u20131011","journal-title":"J Med Virol"},{"key":"956_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12879-014-0556-6","volume":"14","author":"F Pica","year":"2014","unstructured":"Pica F, Gatti A, Divizia M et al (2014) One-year follow-up of patients with long-lasting post-herpetic neuralgia. BMC Infect Dis 14:556","journal-title":"BMC Infect Dis"},{"key":"956_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G et al. (2010) The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 8:37","journal-title":"BMC Med"},{"key":"956_CR38","first-page":"265","volume":"89","author":"WHO","year":"2014","unstructured":"WHO (2014) Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec 89:265\u2013288 (English, French)","journal-title":"Wkly Epidemiol Rec"},{"key":"956_CR39","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/0002512-200825120-00002","volume":"25","author":"RW Johnson","year":"2008","unstructured":"Johnson RW, Wasner G, Saddier P et al (2008) Herpes Zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 25:991\u20131006","journal-title":"Drugs Aging"},{"key":"956_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2334-13-170","volume":"13","author":"S Pinchinat","year":"2013","unstructured":"Pinchinat S, Cebri\u00e1n-Cuenca AM, Bricout H et al (2013) Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 13:170","journal-title":"BMC Infect Dis"},{"key":"956_CR41","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/1346-8138.13639","volume":"44","author":"K Sato","year":"2017","unstructured":"Sato K, Adachi K, Nakamura H et al (2017) Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study. J Dermatol 44:414\u2013422","journal-title":"J Dermatol"},{"key":"956_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/21645515.2017.1264834","volume":"13","author":"C Alicino","year":"2017","unstructured":"Alicino C, Trucchi C, Paganino C et al (2017) Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study. Hum Vaccin Immunother 13:399\u2013404","journal-title":"Hum Vaccin Immunother"},{"key":"956_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1471-2334-10-230","volume":"10","author":"LE Gialloreti","year":"2010","unstructured":"Gialloreti LE, Merito M, Pezzotti P et al (2010) Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 10:230","journal-title":"BMC Infect Dis"},{"key":"956_CR44","first-page":"1091","volume":"72","author":"L Torcel-Pagnon","year":"2017","unstructured":"Torcel-Pagnon L, Bricout H, Bertrand I et al (2017) Impact of underlying conditions on Zoster-related pain and on quality of life following Zoster. J Gerontol A Biol Sci Med Sci 72:1091\u20131097","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"956_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2017.03.014","volume":"308","author":"MA Nagel","year":"2017","unstructured":"Nagel MA, Jones D, Wyborny A (2017) Varicella zoster virus vasculopathy: The expanding clinical spectrum and pathogenesis. J Neuroimmunol 308:112\u2013117","journal-title":"J Neuroimmunol"},{"key":"956_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12879-017-2278-z","volume":"17","author":"F Marra","year":"2017","unstructured":"Marra F, Ruckenstein J, Richardson K (2017) A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis 17:198","journal-title":"BMC Infect Dis"},{"key":"956_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12889-015-1514-y","volume":"15","author":"A Gater","year":"2015","unstructured":"Gater A, Uhart M, McCool R et al. 2015) The humanistic, economic and societal burden of herpes zoster in Europe: a critical review. BMC Public Health 15:193","journal-title":"BMC Public Health"},{"key":"956_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10389-011-0481-8","volume":"20","author":"K Lukas","year":"2012","unstructured":"Lukas K, Edte A, Bertrand I (2012) The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss 20:441\u2013451","journal-title":"Z Gesundh Wiss"},{"key":"956_CR49","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1086\/591132","volume":"47","author":"LA Jackson","year":"2008","unstructured":"Jackson LA, Reynolds MA, Harpaz R (2008) Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clin Infect Dis 47:754\u2013759","journal-title":"Clin Infect Dis"},{"key":"956_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4161\/hv.36160","volume":"11","author":"D Panatto","year":"2015","unstructured":"Panatto D, Bragazzi NL, Rizzitelli E et al (2015) Evaluation of the economic burden of Herpes Zoster (HZ) infection. Hum Vaccin Immunother 11:245\u2013262","journal-title":"Hum Vaccin Immunother"},{"key":"956_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","volume":"73","author":"PH Hobbelen","year":"2016","unstructured":"Hobbelen PH, Stowe J, Amirthalingam G et al. (2016) The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect 73:241\u2013253","journal-title":"J Infect"},{"key":"956_CR52","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40520-017-0782-z","volume":"29","author":"N Valente","year":"2017","unstructured":"Valente N, Cocchio S, Stefanati A et al (2017) Temporal trends in herpes zoster-related hospitalizations in Italy, 2001\u20132013: differences between regions that have or have not implemented varicella vaccination. Aging Clin Exp Res 29:771\u2013779","journal-title":"Aging Clin Exp Res"},{"key":"956_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cger.2016.02.011","volume":"32","author":"K Schmader","year":"2016","unstructured":"Schmader K (2016) Herpes zoster. Clin Geriatr Med 32:539\u2013553","journal-title":"Clin Geriatr Med"},{"key":"956_CR54","first-page":"179","volume":"10","author":"AD Kaye","year":"2010","unstructured":"Kaye AD, Baluch A, Scott JT (2010) Pain management in the elderly population: a review. Ochsner J 10:179\u2013187","journal-title":"Ochsner J"},{"key":"956_CR55","first-page":"16A-20A","volume":"13","author":"J Gnann","year":"2006","unstructured":"Gnann J (2006) Antiviral therapy for herpes zoster. Herpes 13:16A-20A","journal-title":"Herpes"},{"key":"956_CR56","first-page":"35","volume":"14","author":"A Volpi","year":"2007","unstructured":"Volpi A (2007) Severe complications of herpes zoster. Herpes 14 :35\u201339","journal-title":"Herpes"},{"key":"956_CR57","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0163-4453(99)90079-8","volume":"38","author":"PU di Luzio","year":"1999","unstructured":"di Luzio PU, Arpinelli F, Vison\u00e0 G (1999) Herpes zoster and its complications in Italy: an observational survey. J Infect 38:116\u2013120","journal-title":"J Infect"},{"key":"956_CR58","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1017\/CBO9780511601194.015","volume-title":"Varicella-zoster virus: virology and clinical management.","author":"MN Oxman","year":"2000","unstructured":"Oxman MN (2000) Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA (ed) Varicella-zoster virus: virology and clinical management. Cambridge University Press, Cambridge, pp\u00a0246\u2013275"},{"key":"956_CR59","first-page":"1","volume":"23","author":"M Haanp\u00e4\u00e4","year":"2015","unstructured":"Haanp\u00e4\u00e4 M, Rice ASC, Rowbotham MC (2015) Treating herpes zoster and postherpetic neuralgia. PAIN Clin Updates 23:1\u20138","journal-title":"PAIN Clin Updates"},{"key":"956_CR60","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1371\/journal.pmed.0020164","volume":"2","author":"K Hempenstall","year":"2005","unstructured":"Hempenstall K, Nurmikko TJ, Johnson RW et al. (2005) Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2:e164","journal-title":"PLoS Med"},{"key":"956_CR61","unstructured":"VARIVAX Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/15264. Accessed 12 July 2017"},{"key":"956_CR62","unstructured":"ZOSTAVAX Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000674\/WC500053462.pdf. Accessed 12 July 2017"},{"key":"956_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-44348-5","volume-title":"Herpes zoster: postherpetic neuralgia and other complications","author":"CPN Watson","year":"2017","unstructured":"Watson CPN et al (2017) Herpes zoster: postherpetic neuralgia and other complications. Springer, Switzerland"},{"key":"956_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1876326X01206010064","volume":"6","author":"IJ Amanna","year":"2012","unstructured":"Amanna IJ (2012) Balancing the Efficacy and Safety of vaccines in the elderly. Open Longev Sci 6:64\u201372","journal-title":"Open Longev Sci"},{"key":"956_CR65","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/infdis\/jiw462","volume":"214","author":"A Lelic","year":"2016","unstructured":"Lelic A, Verschoor CP, Lau VW et al (2016) Immunogenicity of varicella vaccine and immunologic predictors of response in a cohort of elderly nursing home residents. J Infect Dis 214:1905\u20131910","journal-title":"J Infect Dis"},{"key":"956_CR66","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1086\/514077","volume":"176","author":"RL Redman","year":"1997","unstructured":"Redman RL, Nader S, Zerboni L et al (1997) Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 176:578\u2013585","journal-title":"J Infect Dis"},{"key":"956_CR67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa013441","volume":"347","author":"A Hata","year":"2002","unstructured":"Hata A, Asanuma H, Rinki M et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347:26\u201334","journal-title":"N Engl J Med"},{"key":"956_CR68","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/infdis\/jit344","volume":"208","author":"KM Mullane","year":"2013","unstructured":"Mullane KM, Winston DJ, Wertheim MS et al (2013) Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis 208:1375\u20131385","journal-title":"J Infect Dis"},{"key":"956_CR69","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Eng J Med 372:2087\u20132096","journal-title":"N Eng J Med"},{"key":"956_CR70","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M et al (2016) Impact of the herpes zoster subunit vaccine in adults 70 years of age or older. N Eng J Med 375:1019\u20131032","journal-title":"N Eng J Med"},{"key":"956_CR71","unstructured":"SHINGRIX Product Monograph (Approved 13 October 2017). https:\/\/pdf.hres.ca\/dpd_pm\/00041658.PDF Accessed 20 Dec 2017"},{"key":"956_CR72","unstructured":"European Commission (2018) Community register of medicinal products for human use. http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1272.htm#EndOfPage Accessed 26 Mar 2018"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-018-0956-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-018-0956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-018-0956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:16:09Z","timestamp":1659114969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-018-0956-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s40520-018-0956-3","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"2 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ermanno Zorzoli Congress attendance sponsored by Sanofi. Francesca Pica has no conflict of interest. Giulia Masetti has no conflict of interest. Elisabetta Franco had scientific collaboration with GSK, Merck, Pfizer and Sanofi, and reimbursement for participation to meetings and advisory boards without personal fees. Antonio Volpi was involved in clinical trials for GSK and Achaogen, and participated to advisory board meetings for GSK and Sanofi Pasteur MSD. Giovanni Gabutti has received grants from GlaxoSmithKline Biologicals SA, Sanofi Pasteur MSD, Novartis,Crucell\/Janssen, Seqirus, Sanofi Pasteur, Merck Italy, and Pfizer for being consultant or taking part in advisory board, expert meetings, being a speaker or an organizer of congresses\/conferences, and acting as investigator in clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}